Literature DB >> 20079679

Antivirulence drugs to target bacterial secretion systems.

Christian Baron1.   

Abstract

The rise of resistance of pathogenic bacteria to antibiotics constitutes an increasing risk to public health. Environmental bacteria constitute a large reservoir of resistance determinants and it is predictable that resistance to more antibiotics will be acquired by even more pathogens in future. Innovative strategies are therefore needed to discover novel antibiotic targets as well as alternatives to classical antibiotics. This review will discuss recent advances toward the development of an alternative to classical antibiotics, antivirulence drugs targeting bacterial secretion systems that would disarm rather than kill bacteria. Important progress has been made especially targeting type III secretion systems that are used by many different Gram-negative pathogens. Antivirulence drugs that disarm bacterial pathogens have the potential to be an important alternative or addition to classical antibiotics in future. Copyright 2009 Elsevier Ltd. All rights reserved.

Mesh:

Substances:

Year:  2010        PMID: 20079679     DOI: 10.1016/j.mib.2009.12.003

Source DB:  PubMed          Journal:  Curr Opin Microbiol        ISSN: 1369-5274            Impact factor:   7.934


  49 in total

Review 1.  Protein export systems of Mycobacterium tuberculosis: novel targets for drug development?

Authors:  Meghan E Feltcher; Jonathan Tabb Sullivan; Miriam Braunstein
Journal:  Future Microbiol       Date:  2010-10       Impact factor: 3.165

2.  Type I signal peptidase and protein secretion in Staphylococcus epidermidis.

Authors:  Michael E Powers; Peter A Smith; Tucker C Roberts; Bruce J Fowler; Charles C King; Sunia A Trauger; Gary Siuzdak; Floyd E Romesberg
Journal:  J Bacteriol       Date:  2010-11-12       Impact factor: 3.490

3.  Outside-in assembly pathway of the type IV pilus system in Myxococcus xanthus.

Authors:  Carmen Friedrich; Iryna Bulyha; Lotte Søgaard-Andersen
Journal:  J Bacteriol       Date:  2013-11-01       Impact factor: 3.490

4.  Interfering with outer membrane biogenesis to fight Gram-negative bacterial pathogens.

Authors:  Raffaele Ieva
Journal:  Virulence       Date:  2017-02-17       Impact factor: 5.882

5.  Synthesis and structure-activity relationships of novel phenoxyacetamide inhibitors of the Pseudomonas aeruginosa type III secretion system (T3SS).

Authors:  John D Williams; Matthew C Torhan; Venugopal R Neelagiri; Carson Brown; Nicholas O Bowlin; Ming Di; Courtney T McCarthy; Daniel Aiello; Norton P Peet; Terry L Bowlin; Donald T Moir
Journal:  Bioorg Med Chem       Date:  2015-01-13       Impact factor: 3.641

Review 6.  Chemical inhibitors of the type three secretion system: disarming bacterial pathogens.

Authors:  Miles C Duncan; Roger G Linington; Victoria Auerbuch
Journal:  Antimicrob Agents Chemother       Date:  2012-07-30       Impact factor: 5.191

7.  Staphylococcus aureus virulence attenuation and immune clearance mediated by a phage lysin-derived protein.

Authors:  Hang Yang; Jingjing Xu; Wuyou Li; Shujuan Wang; Junhua Li; Junping Yu; Yuhong Li; Hongping Wei
Journal:  EMBO J       Date:  2018-07-23       Impact factor: 11.598

8.  Cytosporone B, an inhibitor of the type III secretion system of Salmonella enterica serovar Typhimurium.

Authors:  Jianfang Li; Chao Lv; Weiyang Sun; Zhenyu Li; Xiaowei Han; Yaoyao Li; Yuemao Shen
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

Review 9.  Promises and Challenges of the Type Three Secretion System Injectisome as an Antivirulence Target.

Authors:  Alyssa C Fasciano; Lamyaa Shaban; Joan Mecsas
Journal:  EcoSal Plus       Date:  2019-02

10.  An NF-κB-based high-throughput screen identifies piericidins as inhibitors of the Yersinia pseudotuberculosis type III secretion system.

Authors:  Miles C Duncan; Weng Ruh Wong; Allison J Dupzyk; Walter M Bray; Roger G Linington; Victoria Auerbuch
Journal:  Antimicrob Agents Chemother       Date:  2013-12-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.